Status
Conditions
Treatments
About
A randomised placebo controlled, double-blind, 30 Volunteer trial of Elio™ administered 2.4 grams per day in assessing its effects on post-exercise strength recovery and increases in markers associated with muscle injury and exertion.
Full description
Periods of intense physical activity and exertion can lead to disruption of normal muscle homeostasis and the resultant muscle injury and recovery can impact upon quality of life especially in adult populations. Recovery post-exercise is therefore important to all active people.
There is a link between high-intensity exercise and reduced power and performance in the following exercise sessions. The effect on performance is measures as a reduced muscle force production or loss in strength and can correlate with delayed onset muscle soreness (DOMS). The reduced power/performance seen 24 hours - 7days post-exercise is affected by recovery methods applied, individual fitness levels and intensity of exercise injury.
Several theories have been proposed to explain the mechanisms underlying DOMS. These include inflammation and muscle damage.
Exercise-induced muscle damage is a transient phenomenon caused by unfamiliar, damaging exercise and is characterized by structural damage to myofibers and secondary inflammation. Signs and symptoms often persist for several days after exercise and typically include muscle soreness, elevated blood levels of intramuscular enzymes such as creatine kinase (CK), lactate dehydrogenase (LDH) and myoglobin (MB) that often result in elevations in circulating markers of inflammation such as C-reactive protein (CRP) and various interleukins. To date, extensive research has been published that explore the many recovery strategies purported to minimize indirect markers of muscle damage.
However, from a nutritional standpoint the results are weak. It is therefore important to develop nutritional products that can lessen the impact of these injuries' individuals succumb to or expedite their recovery.
Nutritional recovery strategies purported to minimise indirect markers of muscle damage and improve the inflammatory response can positively influence the recovery process after damaging exercise.
These strategies could in turn be used to prime the muscle for physical challenges.
Furthermore, there is a clear absence of natural approaches with proven evidence to address DOMS and the resulting performance declines.
Therapies such as non-steroidal anti-inflammatory drugs (NSAIDs) can be taken in the short term to reduce DOMS associated pain and inflammation. However, these drugs do not address performance strength loss linked to DOMS.
Acute injuries to discrete muscle groups can be indirectly detected by an array of systemic biomarkers, which become elevated at various time-points following the event.
This array of biomarkers represents key biochemical processes in muscle homeostasis, cellular integrity, mitochondrial function and inflammation.
Preliminary investigations in vitro and in vivo suggest that the administration of peptides isolated from the protein extract of fava beans, which constitute Elio™, can augment muscle protein synthesis (i.e. phospo-S6) and attenuate proteolytic signaling (i.e. Fbxo32 and Trim63) and surrogate inflammatory markers (TNFα and IL6). Thus, supporting the use of this hydrolysate in maintaining muscle homeostasis and function.
With the present study the investigators will investigate whether daily dietary supplementation of Elio™, over the course of 15 days can prime the muscle by improving strength recovery and attenuating the expression of systemic markers associated with muscle injury and over exertion following resistance type exercise in a healthy male population.
Objectives
To determine the effect of Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract, on strength recovery and markers of muscle health, injury and function following strenuous resistance type exercise in male volunteers, aged between 30 and 45 years old following 17 days of supplementation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Alcohol or drug abuse in past year
Participation in any other clinical trial in the last 3 months from time of randomisation
Volunteer has a known allergy to the test material's active or inactive ingredients
Volunteers with unstable medical conditions
Any complaints that could interfere with ability to exercise
Individuals who are cognitively impaired and/or who are unable to give informed consent
Any co-morbidities interacting with mobility or muscle metabolism of the lower limbs (e.g., arthritis, spasticity/rigidity, all neurological disorders and paralysis)
Creatine supplements, anticoagulants, corticosteroids, growth hormones,
testosterone, immunosuppressants, or exogenous insulin over the previous three months
Presence or history of neurological disorders or significant psychiatric illness.
Any other condition which in the Investigator's opinion may adversely affect the volunteer's ability to complete the study or its measures or which may pose significant risk to the volunteer
Participation in resistance or aerobic exercise within 48 hours of the test days
Participation in > 3 High-intensity Exercise sessions per Week
Undertake no recovery methods such as sea swims, foam rolling, cryotherapy or undue stretching during Days 14-17.
Have been in contact with a suspected or confirmed case of Covid-19 in the previous 14 days
Are Hepatitis A or B positive, HIV positive or have had a sexual partner who is infected with hepatitis or HIV
Primary purpose
Allocation
Interventional model
Masking
44 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Thomas Ball; Thayse Passos
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal